Cantor Fitzgerald analyst Carter Gould initiated coverage of AbbVie (ABBV) with an Overweight rating and $210 price target AbbVie offers a “compelling mix of growth and defense” with a differentiated sales growth profile, good visibility on key near-term drivers with low clinical risk, no major near-to-mid-term loss of exclusivity with “the Humira pain behind it,” and a lack of a major binary data catalyst over 2025, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target lowered to $200 from $223 at BofA
- Options Volatility and Implied Earnings Moves This Week, April 21 – April 25, 2025
- AbbVie Hold Rating: Modest Forecast Adjustments Amid Tariff and Pricing Concerns
- Lenz Therapeutics assumed with an Overweight at Piper Sandler
- Block, Simon, Sirius, AbbVie, Apple: Trending by Analysts